Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) rose 7.1% on Friday . The stock traded as high as $6.42 and last traded at $6.47. Approximately 1,601,358 shares were traded during mid-day trading, a decline of 8% from the average daily volume of 1,742,398 shares. The stock had previously closed at $6.04.
Analyst Upgrades and Downgrades
Separately, HC Wainwright restated a "buy" rating and issued a $13.00 target price on shares of Tango Therapeutics in a research report on Monday, April 14th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $10.50.
Check Out Our Latest Analysis on TNGX
Tango Therapeutics Stock Performance
The company has a 50 day moving average price of $5.19 and a 200 day moving average price of $3.08. The firm has a market cap of $752.15 million, a price-to-earnings ratio of -5.71 and a beta of 1.63.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its earnings results on Tuesday, August 5th. The company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35). The firm had revenue of $3.18 million during the quarter, compared to analysts' expectations of $6.41 million. Tango Therapeutics had a negative return on equity of 62.75% and a negative net margin of 322.67%. On average, research analysts forecast that Tango Therapeutics, Inc. will post -1.19 earnings per share for the current year.
Institutional Trading of Tango Therapeutics
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TCG Crossover Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $33,174,000. Boxer Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $32,077,000. Gilead Sciences Inc. acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $15,000,000. Farallon Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $12,360,000. Finally, Nantahala Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the 4th quarter worth approximately $8,666,000. 78.99% of the stock is owned by hedge funds and other institutional investors.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
See Also
Before you consider Tango Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tango Therapeutics wasn't on the list.
While Tango Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access